In a media briefing streamed live on ... 11/12) Novavax yesterday announced that the US Food and Drug Administration (FDA) has released a clinical hold on its new drug application for its COVID-flu ...
The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...
Novavax, Inc., based in Gaithersburg, Maryland, is a global biotechnology company focused on developing and commercializing innovative protein-based vaccines to combat serious infectious diseases, ...
Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...
In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...
GlobalData on MSN23h
FDA clears Novavax to resume trials of Covid-19 and flu combo vaccineNovavax has received the green light from the US Food and Drug Administration (FDA) to resume clinical trials for its ...
Back in November 2023, pharmaphorum travelled to Uppsala, Sweden, for a Novavax press conference, the company celebrating a decade of doing what it does best: vaccines. From COVID-19 to malaria ...
Inovio Pharmaceuticals Inc. 0.36% $143.32M ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback